



Table S1. Assumptions adopted for each molecule.

Molecule ¹	Uptake		Price	
	Missing data	Assumption	Missing data	Assumption
SOM	Data on originator uptake between 2009 and 2015	-Biosimilar market share between 2011 and 2015 from Almarza et al., [42]. - Biosimilar market share in 2009 from Rovira et al. [43].	Biosimilar price prior to RPO-2014	Biosimilar price prior to RPO-2014 is 10% greater than the RP according RPO-2014
FIL		Full data available	Biosimilar price prior to RPO-2014	Biosimilar price prior to RPO-2014 is 10% greater than the RP according RPO-2014
EPO	- Data on originator uptake between 2009 and 2015 - Data on epoetin zeta biosimilar uptake between 2009 and 2015	-Biosimilar market share between 2011 and 2015 from Almarza et al., [42]. - Biosimilar market share in 2009 from Rovira et al. [43] - The annual variation is assumed to be proportional to the total uptake of the molecule	Biosimilar price prior to RPO-2014	Biosimilar price prior to RPO-2014 is 10% greater than the RP according RPO-2014
FOL	Data on originator and biosimilar uptake between 2014 and 2016	- Biosimilar market share in 2015 extracted from Comunitat Valenciana, [44]. - The total volume of the molecule in 2015 is taken as the total market in 2014. Biosimilar, marketed in November 2014, is assumed to capture 20% of 2015 market.	Biosimilar price prior to RPO-2015	Biosimilar price prior to RPO-2015 is 10% greater than the RP according RPO-2015
INF		Full data available		Full data available
INS		Full data available	Biosimilar price prior to RPO-2016	Biosimilar price prior to RPO-2016 is 10% greater than the RP according to RPO-2016
ETA		Full data available		Full data available
CHO		Full data available	Biosimilar price prior to RPO-2017	Biosimilar price prior to RPO-2017 is 10% greater than the RP according RPO-2017
RIT		Full data available		Full data available
TRA		Full data available		Full data available
ENO		Full data available	Biosimilar price prior to RPO-2019	Biosimilar price prior to RPO-2019 is 10% greater than the RP according RPO-2019
ADA		Full data available		Full data available
PEG		Full data available		Full data available

¹ SOM: somatropin; FIL: Filgrastim; EPO: epoetin; FOL: follitropin alfa; INF: infliximab; INS: insuline glargine; ETA: etancercapt; CHO: chondroitin sulfate; RIT: rituximab; TRA: trastuzumab; ENO: sodium enoxaparin; ADA: adalimumab; PEG: pegfilgrastim.